Borealis Biosciences has appointed Christian Hordo as chief executive officer as well as three new board members. Borealis was launched in August 2024 by Novartis through a collaboration with the venture capital group Versant Ventures to focus on RNA therapies for kidney disease. The start-up also had an infusion of $30 million in an extension of a Series A financing led by Westlake BioPartners, bringing its total committed capital to $180 million.
Mr Hordo previously was executive vice president and chief business officer of Sana Biotechnology and prior to that, was head of business development and myeloma programme lead at Juno Therapeutics. Mr Hordo has an MSc in medical genetics and microbiology from the University of Toronto, Canada. The three board directors are David Allison, managing director at Westlake, Tom Frohlich, CEO of Jade Biosciences and Catherine Thut, therapeutic area strategy head, TAx at Novartis.
Borealis announced the appointments on 19 December 2024.
Copyright 2025 Evernow Publishing Ltd.